CVE:HEM Hemostemix (HEM) Stock Price, News & Analysis → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free HEM Stock Alerts C$0.04 -0.01 (-10.00%) (As of 04/24/2024 05:23 PM ET) Add Compare Share Share Today's RangeC$0.04▼C$0.0550-Day RangeC$0.05▼C$0.1052-Week RangeC$0.04▼C$0.18Volume82,500 shsAverage Volume41,030 shsMarket CapitalizationC$4.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesInsider TradesStock AnalysisChartHeadlinesInsider Trades Get Hemostemix alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Hemostemix Stock (CVE:HEM)Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.Read More HEM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HEM Stock News HeadlinesMarch 7, 2024 | finanznachrichten.deHemostemix Inc.: Hemostemix Announces Engagement of Oak Hill Asset Management Inc.March 7, 2024 | finance.yahoo.comHemostemix Announces Engagement of Oak Hill Asset Management Inc.April 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 20, 2024 | theglobeandmail.comHemostemix: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (HEM)February 19, 2024 | theglobeandmail.comHemostemix: Top 10 Undervalued Biotechnology Industry Stocks (HEM)February 6, 2024 | finance.yahoo.comHemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental SciencesJanuary 19, 2024 | morningstar.comHemostemix Inc HMTXFOctober 30, 2023 | finanznachrichten.deHemostemix Inc.: Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart DiseaseApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… October 30, 2023 | finance.yahoo.comHemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart DiseaseOctober 20, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc down on Thursday (HEM)August 29, 2023 | finance.yahoo.comHemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant ApplicationsAugust 8, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc up on Friday (HEM)June 28, 2023 | finanznachrichten.deHemostemix Inc.: Hemostemix Closes $403,539 of the Unit Private PlacementJune 28, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc up on Tuesday (HEM)June 28, 2023 | finance.yahoo.comHemostemix Closes $403,539 of the Unit Private PlacementJune 27, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc down on Monday (HEM)June 24, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc flat on Wednesday (HEM)June 22, 2023 | marketwatch.comHemostemix's Private Placement Use of ProceedsJune 17, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc down on Friday (HEM)June 2, 2023 | msn.comHemostemix to raise $1.2M through private placement of unitsMay 3, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc flat on Tuesday (HEM)May 2, 2023 | finance.yahoo.comHemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant CompanyApril 29, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc flat on Friday (HEM)April 21, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc flat on Thursday (HEM)April 20, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc up on Wednesday (HEM)April 19, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc down on Tuesday (HEM)See More Headlines Receive HEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:HEM CUSIPN/A CIKN/A Webwww.hemostemix.com Phone+1-403-3409207FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-3,170,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-165.67% Debt Debt-to-Equity RatioN/A Current Ratio0.25 Quick Ratio0.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow10.77 Book ValueC($0.08) per share Price / Book-0.56Miscellaneous Outstanding Shares89,790,000Free FloatN/AMarket CapC$4.04 million OptionableNot Optionable Beta0.55 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Thomas A. Smeenk B.A. (Age 62)BA Hons, Co-Founder, President, CEO & Director Comp: $308kMs. Christina Wu CPAInterim Chief Financial OfficerPeter PavlinVice President of OperationsDr. Fraser C. Henderson Sr.M.D., Chief Medical OfficerKey CompetitorsInnovotechCVE:IOTRevive TherapeuticsCVE:RVVQuest PharmaTechCVE:QPTPacgen Life Science Co. (PBS.V)CVE:PBSMedifocus Inc. (MFS.V)CVE:MFSView All CompetitorsInsidersThomas SmeenkBought 20,000 shares on 12/14/2023Total: C$1,400.00 ($0.07/share)Thomas SmeenkBought 13,000 shares on 12/5/2023Total: C$910.00 ($0.07/share)Thomas SmeenkBought 25,000 shares on 11/7/2023Total: C$1,750.00 ($0.07/share)View All Insider Transactions HEM Stock Analysis - Frequently Asked Questions How have HEM shares performed in 2024? Hemostemix's stock was trading at C$0.07 at the beginning of 2024. Since then, HEM shares have decreased by 35.7% and is now trading at C$0.05. View the best growth stocks for 2024 here. What other stocks do shareholders of Hemostemix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hemostemix investors own include Iplayco (IPC), Capricor Therapeutics (CAPR), Gene Biotherapeutics (CRXM), Camber Energy (CEI), Auxly Cannabis Group (CBWTF), Cannabis Science (CBIS), Beazer Homes USA (BZH), Big Tree Group (BIGG), Asterias Biotherapeutics (AST) and How do I buy shares of Hemostemix? Shares of HEM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:HEM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemostemix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
